• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cumberland Pharmaceuticals Inc.

    3/9/26 5:03:48 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPIX alert in real time by email
    DEFA14A 1 a2025proxy-defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934
    Filed by the Registrant þ
    Filed by a Party other than the Registrant o
    Check the appropriate box:
    o  Preliminary Proxy Statement
    o  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    o  Definitive Proxy Statement
    þ  Definitive Additional Materials
    o  Soliciting Material Pursuant to §240.14a-12
    CUMBERLAND PHARMACEUTICALS INC.

    Payment of Filing Fee (Check the appropriate box):

    þ  No fee required.
    o  Fee paid previously with preliminary materials
    o  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    1


    cumberlandlogoa02a01.jpg

    As a shareholder of Cumberland Pharmaceuticals Inc. you have the option of voting your shares electronically through the Internet, eliminating the need to return the proxy card. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated and returned the proxy card. Votes submitted electronically over the Internet or by mobile device must be received by 11:59 p.m., Eastern Time, on April 20, 2026.
    Vote Your Proxy on the Internet:Vote Your Proxy on your Mobile:Vote Your Proxy via the mail:
    OROR
    Go to www.cstproxyvote.com
    Have your proxy card available when you access the above website. Follow the prompts to vote your shares.On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares.Mark, sign, and date your proxy card, then detach it, and return it in the postage-paid envelope provided.
    PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE
     VOTING ELECTRONICALLY OR BY PHONE

    ÚFOLD AND DETACH HERE AND READ THE REVERSE SIDE Ú

    PROXY
    This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this Proxy will be voted FOR Proposals 1, 2, 3 AND Every Three Years for Proposal 4. The Board recommends a vote FOR Proposals 1,2,3 AND Every Three Years for Proposal 4.
    xa01.jpg
    ForAgainstAbstain
    1. For the election as directors of the nominees listed below, except to the extent that authority is specifically withheld.

      
    FOR all Nominees listed to the left
    WITHHOLD AUTHORITY to vote (except as marked to the contrary for all nominees listed to the left
    2. To ratify the appointment of Carr, Riggs & Ingram, L.L.C. as independent registered accounting firm of the Company for fiscal year ending December 31, 2026.
    ooo
    ForAgainstAbstain
    NOMINEES: (1) Mr. Kenneth Krogulski (2) Ms. Caroline Young oo
    3. To provide advisory approval of the compensation of the Company's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.
    ooo
    Every YearEvery Other YearEvery Three YearsAbstain
    (INSTRUCTION: To withhold authority to vote for any individual nominee, write that nominee's name on the space provided below.)
    4. To provide advisory approval of the frequency of the advisory vote on the compensation of the Company’s named executive officers.
    o oooo
    In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting.
    I understand that I may revoke this Proxy only by: (i) written instructions to that effect, signed and dated by me, which must be actually received by the Corporate Secretary prior to the commencement of the Annual Meeting; (ii) properly submitting to the Company a duly executed proxy bearing a later date; OR (iii) appearing at the Annual Meeting and voting in person.
    COMPANY ID:
    PROXY NUMBER:
    ACCOUNT NUMBER:
    Signature _________________________________ Signature if Held Jointly____________________________________ Date____________ , 2026.
    Please sign exactly as your name appears on your stock certificate. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If the
    shares are owned by a corporation, sign in the full corporate name by the President or other authorized officer. If the shares are owned by a Partnership, sign in the name of the Partnership name by an authorized person.
    2









    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held April 21, 2026

    The Notice, Proxy Statement, and our Annual Report on Form 10-K for the year ended December 31, 2025 are available at:
    http://www.cstproxy.com/cumberlandpharma/2026





    ▼ FOLD AND DETACH HERE AND READ THE REVERSE SIDE ▼


    THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF
    CUMBERLAND PHARMACEUTICALS INC.
    NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
    To Be Held April 21, 2026

    The undersigned hereby appoints A.J. Kazimi and Kenneth J. Krogulski, or either of them, as proxies, with full power of substitution, and hereby authorizes each of them to represent and vote, as designated on the reverse side, all of the shares of Common Stock of Cumberland Pharmaceuticals Inc., held of record by the undersigned on February 27, 2026 at the Annual Meeting of Shareholders to be held at the Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203 on Tuesday, April 21, 2026, at 9:30 a.m. Central Time, or any adjournment(s) or postponement(s) thereof, with all powers which the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the instructions specified on the reverse side.

    THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTIONS ARE GIVEN, THIS PROXY WILL BE VOTED FOR ALL OF THE DIRECTOR NOMINEES NAMED IN PROPOSAL 1 ON THE REVERSE SIDE AS WELL AS PROPOSALS 2 AND 3 AND EVERY THREE YEARS FOR PROPOSAL 4. THE PROXIES NAMED ABOVE ARE HEREBY AUTHORIZED TO VOTE IN THEIR DISCRETION UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT(S) OR POSTPONEMENT(S) THEREOF.



    (Continued, and to be marked, dated and signed, on the other side)
    3
    Get the next $CPIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

    Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland en

    3/3/26 5:00:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Joint U.S. Commercialization of RedHill's Talicia® Commences

    The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activitiesH. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H

    2/25/26 7:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Cumberland Pharmaceuticals Inc.

    DEFA14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    3/9/26 5:03:48 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cumberland Pharmaceuticals Inc.

    DEF 14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    3/9/26 5:01:59 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cumberland Pharmaceuticals Inc.

    10-K - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)

    3/6/26 8:54:38 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline bought $398 worth of shares (121 units at $3.29), increasing direct ownership by 0.37% to 32,942 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:36:28 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.60% to 43,938 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:35:26 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J bought $862 worth of shares (262 units at $3.29), increasing direct ownership by 0.00% to 5,700,030 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    9/12/25 8:34:18 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Young Caroline increased direct ownership by 0.20% to 33,309 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    1/6/26 5:05:10 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jones James increased direct ownership by 0.60% to 45,063 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    1/6/26 5:04:25 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Kazimi A J increased direct ownership by 0.00% to 5,701,155 units (SEC Form 4)

    4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)

    1/6/26 5:03:52 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

    Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland en

    3/3/26 5:00:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

    NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®.  Cumberland has assumed responsibility for the distribution and sales promotion of the brand in the U.S. under the co-commercialization agreement with RedHill Biopharma. Talicia is an FDA-approved oral capsule indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin and

    2/25/26 7:00:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

    NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at

    2/24/26 4:05:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Leadership Updates

    Live Leadership Updates

    View All

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

    NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka.  Brown is an attorney at Adams and Reese LLP, a

    7/19/22 9:25:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/9/24 5:27:23 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/10/23 5:01:42 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cumberland Pharmaceuticals Inc.

    SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)

    2/14/22 5:17:27 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care